Member Info for xviolet

In a previous investor meet they referred to contracts which - presumably - they didn't RNS. Perhaps they only put out an RNS for really big contracts.

I remember reading an interview with a very seasoned AIM trader - someone who turned a few thousand pounds into a few hundred thousand pounds and then lost it all (and made it back again, over a few years). He said 'read the RNS'. Otherwise I guess you get lost in speculation and uncertainty. So what Tim says in the interviews - for me, is not helpful. W hat matters is what is in the RNS. I work from that. So...to quote:

"...the current cash runway now extends well into Q4 2026. The Company reaffirms it has no intention to raise further funds and will look to further strengthen its cash position as a result of deals with potential commercial partners."

I would assume that only carries for a year or so. Its not like the RNS said they will never raise funds ever ever again. But I guess you have to make your peace with the information that is available, take your position and then go off and do something more interesting with your time. Whats the point in driving yourself mad with the uncertainty?

That is the thing with this share.

the right news. from time to time.

drops. its happened before.

low mcap. so primed.

Up and up.

should go up on the zinc/silver from Ireland

should go up on the uranium

how many uranium plays on AIM - early stages...always the best time to get in if you want real multiples (10 bags)

do the BOD have skin in the game? read the RNS.

funds raised. now 4wds.

You've got uranium

plus...zinc/silver newslflow-results

perhaps the company already have a £ value or offer on the zinc/silver asset

I need to look at today's financing...but it does seem BOD have skin in game.

Think that's how you spell it.

Wonder if this is connected to the recent buying that took the sp up?

"just when you least expect it, the unexpected always happens". (Joe Orton).

Thanks

in the cart??

Well we haven't heard about CIDP for a long-time.

And perhaps some of the last year's £ could be used for some lab work on the fungal product- I think there's a fungal product in the pipeline.

There was one Proactive Interview where Tim said anyone could just call him up - his number is not secret. Maybe I should give him a bell and ask about Avion. Not sure I really fancy it but I'll have a think.

How is the cart?

anything in there?

The Type M Endotype news that IMM has been touting presumably increases the probability of a Lupuzor P3 being successful. I don't know to what degree, in percentage terms. After the Sep 2022 FDA update perhaps that is what IMM have been working on - they have been trying to make that P3 more likely to succeed?

For all the talk of deals there is only one deal that we know about - and that is the deal with Avion. You could argue that the recent work on P140 was oriented or at least began with the intention of making that P3 trial and Avion's backing more probable.

I can't comment on imagined take-over scenarios - I can't make a realistic assessment of IMM's claims and their potential value. Certainly there is still no external verification of IMM's claims or P140's uses and efficacy. But there is one deal on the table. And perhaps IMM made an effort to action that deal.

That is on my research list. Must find out what it is.

Bad news out of the way. So good news must be sitting somewhere.

thanks prof

lets keep it real.

btw if someone wanted to look at the down-side - doing it from research and not petulance/******** is more likely to produce useful results. nolupus made an interesting point about pharma and value. and whilst i was pleased to see the founding scientist here awarded/rewarded - presumably by her peers - that alone does not prove value or potential commercial value. but then for small investors value is often in the companies that vc or larger companies have not noticed or have over-looked.

Why does no one here talk about avion/alora or look at the financial position of those companies.

or how they have financed and supported any research they have conducted to date.

its on my research list. but if anyone can do it before I have a chance...that would be great. and I don't mean use AI - it wastes electricity and its often wrong. I've noticed that some AIs don't read all the RNS's and related documentation - so the answers you get are incorrect and incomplete.

No volume after conference? SCLP LSE Board think volume on their stock was connected to conference.

But no volume here.

I was looking at Alora (parent of Avion pharma) - they seem to be big enough. But no RNS.

Not much else I can add.

Thanks Tyke

well done.

Malletp

the trial data has some value....

thats a nice perspective. thanks.

its very interesting to hear everyone's perspectives. and good that tyke is reaching out to TB. more information is always helpful.

Yes falling atm. Maybe touching 0.4s again.

Lets see if its possible to buy at that price.

Well...at first glance re the CLNs...it looks like bad news out of the way.

so further news releases and conversion can follow. in time.

Sorry I've been away and haven't contributed anything.

I am aware that funding for trials is not easy to access. So I am not surprised by last week's RNS. But I hope there is a way that some patients may receive the treatment if it can help them.

I am looking carefully at the Kirkstall CLN RNS. I need more time to get a better understanding of that RNS. And its implications.

And I look forwards to seeing the company make progress in the imaging sector.

There is a TG group for IBAI already. Perhaps someone could post the link.